Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07491172 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 14 words
    • Site details revised at 4 of 17 sites
  2. Site details revised at 1 of 17 sitesv6
  3. Study sites: 19 to 17v5
  4. Study sites: 21 to 19v4
  5. Trial sites expanded: 18 → 21 locationsv3
  6. Site details revised at 3 of 18 sitesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Trial Details
NCT Number NCT07491172
Lead Sponsor CRISPR Therapeutics AG
Conditions
(from sponsor)		 Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG) +2 more
Related terms Dyslipidemias, Homozygous Familial Hypercholesterolemia, Hypercholesterolemia, Hyperlipoproteinemia Type V, Hypertriglyceridemia, Lipid Metabolism Disorders, Metabolic Diseases
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov